Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
Abstract Intracellular antibodies are valuable tools for target validation studies for clinical situations such as cancer. Recently we have shown that antibodies can be used for drug discovery in screening for chemical compounds surrogates by showing that compounds could be developed to the so-calle...
Guardado en:
Autores principales: | Tomoyuki Tanaka, Jemima Thomas, Rob Van Montfort, Ami Miller, Terry Rabbitts |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c468ab122a7546998735702fb5e4d92b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Camilo E. Quevedo, et al.
Publicado: (2018) -
Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins
por: Adam Leach, et al.
Publicado: (2021) -
WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation
por: Woo-Jeong Jeong, et al.
Publicado: (2019) -
Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
por: Seung-Min Shin, et al.
Publicado: (2017) -
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Timothy H. Tran, et al.
Publicado: (2021)